RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New transplant timing strategy may tame High-Risk blood cancers
Disease control OngoingThis study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
New drug combo after transplant shows promise for tough hodgkin lymphoma
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can help prevent Hodgkin lymphoma from coming back after a stem cell transplant. It includes 62 people with high-risk lymphoma that returned or didn't respond to earlier treatments. The goal is t…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New weekly combo shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether giving a targeted drug (brentuximab vedotin) weekly, with or without another immune-boosting drug (nivolumab), can shrink tumors in people with CD30+ lymphoma that has come back or stopped responding to standard treatment. About 28 adults with relapsed or…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
Promising combo for tough hodgkin lymphoma cases shows strong response
Disease control OngoingThis study tested a combination of the immunotherapy drug nivolumab and chemotherapy (ICE) in 78 people with Hodgkin lymphoma that returned or didn't respond to initial treatment. The goal was to see if this approach could shrink tumors enough to allow a stem cell transplant. The…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:00 UTC